u/ferran_dahlberg

Agreed — somebody is at exactly the point you were at, reading this, and it will land differently for them than any success story.

Right — mechanism gives you a direction.

Disagreeing with this specific inference — that is a preclinical result being read as human pharmacology.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

a mistake described in detail is worth more than a success described vaguely

a peer-to-peer call is often faster than a written appeal

Same pattern here. It settled at a stable dose without me doing anything clever.

smaller meals, earlier, is the boring advice that works

Ask for the batch-specific certificate before payment. Any operation with a quality system behind it can produce one; the request costs you nothing and it filters hard.

Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.

Same pattern here. It settled at a stable dose without me doing anything clever.

That conflates receptor affinity with clinical potency. They are related and they are not the same thing.

Do you have anything in writing from before the payment?

protein and resistance training, that is the entire intervention

Started weighing protein rather than estimating it. The gap between what I thought and what I ate was embarrassing.

Not convinced. Cross-trial comparison between two programmes with different populations and designs is not a comparison.

sulphur burps are unpleasant and they are not dangerous

the diagnosis code on the claim is doing more work than anything you write

Correction: those scans are from different machines, and the difference you are describing is within the measurement error.

lina_bruun is right that protein becomes a logistics problem when appetite drops.

Same view. The second-level appeal is where mine turned, after a first-level denial that looked final.

smaller meals, earlier, is the boring advice that works

Adding to this — holding the dose rather than stepping is the option people forget they have.

phase 2 finds a dose, phase 3 measures the effect

Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.

That reads like advice, and none of us can give it. Describe what you did, not what somebody else should do.

a shop that will only talk off-platform has told you something

Cosigning on GIP. The genuinely interesting thing is that the biology is not settled and the clinical result is nonetheless robust.

Right — trial participants get structured support. Comparing yourself to a trial mean is comparing across two different interventions.

Most of what gets posted here is procedural rather than dramatic: a step skipped, a document not requested, a temperature not considered, a pace chosen out of impatience.

The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.

a mistake described in detail is worth more than a success described vaguely

Severe, or unpleasant? They are genuinely different questions and the answers diverge.

Discontinuation rates are a tolerability result. A trial with a strong efficacy number and heavy discontinuation is telling you two things and people only quote one.

Hydration status and fasting state affect the lean mass estimate. Standardising both is the difference between a comparison and a coin toss.

nobody warns you about how much of this is timing rather than dose

ask for the denial reason in writing, always

Are you comparing against your own baseline or against a published average?

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

The press release said that; the publication says something more hedged. Worth reading both.

I would not skip the peer-to-peer. It is often the fastest route and it costs a phone call.

Are you comparing against your own baseline or against a published average?

fibre and water before you buy anything to fix it